DnB Asset Management
RNAM

DnB Asset Management’s Avidity Biosciences RNAM Stock Holding History

DnB Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,474
Closed -$326K – 767
2025
Q3 		$326K Buy
+7,474
New +$302K ﹤0.01% 691

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DnB Asset Management's RNAM Position: Q4 2025 in Review

DnB Asset Management sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 7,474 shares — an estimated $326K sold.

DnB Asset Management first reported a position in RNAM in Q3 2025 and held it in 1 quarter. The position peaked at $326K in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • DnB Asset Management reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • DnB Asset Management sold 7,474 Avidity Biosciences shares in Q4 2025, an estimated $326K.
  • DnB Asset Management first reported a position in Avidity Biosciences in Q3 2025 and held it in 1 quarter.
  • DnB Asset Management's Avidity Biosciences position peaked at $326K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on DnB Asset Management's 13F filing for Q4 2025, filed 5 Feb 2026.